Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 401

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

Visscher, Henk, Ross, Colin J.D., Rassekh, S. Rod, Barhdadi, Amina, Dubé, Marie-Pierre, Al-Saloos, Hesham, Sandor, George S., Caron, Huib N., van Dalen, Elvira C., Kremer, Leontien C., van der Pal, Helena J., Brown, Andrew M.K., Rogers, Paul C., Phillips, Michael S., Rieder, Michael J., Carleton, Bruce C., Hayden, Michael R., Canadian Pharmacogenomics Network for Drug Safety Consortium·2012·Journal of Clinical Oncology

Abstract

Purpose: Anthracycline-induced cardiotoxicity (ACT) is a serious adverse drug reaction limiting anthracycline use and causing substantial morbidity and mortality. Our aim was to identify genetic variants associated with ACT in patients treated for childhood cancer. Patients and Methods: We carried out a study of 2,977 single-nucleotide polymorphisms (SNPs) in 220 key drug biotransformation genes in a discovery cohort of 156 anthracycline-treated children from British Columbia, with replication in a second cohort of 188 children from across Canada and further replication of the top SNP in a third cohort of 96 patients from Amsterdam, the Netherlands. Results: We identified a highly significant association of a synonymous coding variant rs7853758 (L461L) within the SLC28A3 gene with ACT (odds ratio, 0.35; P = 1.8 × 10−5 for all cohorts combined). Additional associations (P < .01) with risk and protective variants in other genes including SLC28A1 and several adenosine triphosphate–binding cassette transporters (ABCB1, ABCB4, and ABCC1) were present. We further explored combining multiple variants into a single-prediction model together with clinical risk factors and classification of patients into three risk groups. In the high-risk group, 75% of patients were accurately predicted to develop ACT, with 36% developing this within the first year alone, whereas in the low-risk group, 96% of patients were accurately predicted not to develop ACT. Conclusion: We have identified multiple genetic variants in SLC28A3 and other genes associated with ACT. Combined with clinical risk factors, genetic risk profiling might be used to identify high-risk patients who can then be provided with safer treatment options.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.34.3467

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 401

Metadata

Authors
Visscher, H., Ross, C. J. D., Rassekh, S. R., Barhdadi, A., Dubé, M.-P., Al-Saloos, H., Sandor, G. S., Caron, H. N., van Dalen, E. C., Kremer, L. C., van der Pal, H. J., Brown, A. M. K., Rogers, P. C., Phillips, M. S., Rieder, M. J., Carleton, B. C., Hayden, M. R., & Canadian Pharmacogenomics Network for Drug Safety Consortium
Venue
Journal of Clinical Oncology
Published
2012-05-01
Volume
30
Issue
13
Pages
1422-1428
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2152922562
Cited by
401
References
36
FWCI
16.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. https://app.cochat.ai/papers/10.1200/jco.2010.34.3467
The paper
Visscher, H., Ross, C. J. D., Rassekh, S. R., Barhdadi, A., Dubé, M.-P., Al-Saloos, H., Sandor, G. S., Caron, H. N., van Dalen, E. C., Kremer, L. C., van der Pal, H. J., Brown, A. M. K., Rogers, P. C., Phillips, M. S., Rieder, M. J., Carleton, B. C., Hayden, M. R., & Canadian Pharmacogenomics Network for Drug Safety Consortium. (2012). Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.34.3467

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.